| BMC Nephrology | |
| Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report | |
| Véronique Frémeaux-Bacchi1  Laura Braun-Parvez2  Bruno Moulin2  Sophie Caillard2  Jérome Olagne2  Michel Greget3  Marie-Pierrette Chenard4  Philippe Baltzinger5  Marion Munch5  Laurence Kessler6  Thibault Bahougne7  | |
| [1] Assistance Publique-Hôpitaux de Paris, Laboratoire d’Immunology, Hôpital Européen Georges Pompidou, Paris, France;INSERM UMR S1138, Complément et Maladies, Centre de Recherche des Cordeliers, Paris, France;Service de Néphrologie et Transplantation, Hôpital Civil, Strasbourg, France;Service de radiologie, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France;Service d’Anatomie Pathologique, Hôpital de Hautepierre, Hôpitaux Universitaires de Strasbourg, Strasbourg, France;Service d’Endocrinologie, Diabète et Nutrition, Hôpitaux Universitaires de Strasbourg, 1 Place de L’Hôpital, F-67000, Strasbourg, France;Service d’Endocrinologie, Diabète et Nutrition, Hôpitaux Universitaires de Strasbourg, 1 Place de L’Hôpital, F-67000, Strasbourg, France;Inserm UMR 1260, Nanomédecine Régénérative, Fédération de médecine Translationnelle, Université de Strasbourg, Strasbourg, France;Service d’Endocrinologie, Diabète et Nutrition, Hôpitaux Universitaires de Strasbourg, 1 Place de L’Hôpital, F-67000, Strasbourg, France;Institut des Neurosciences Cellulaires et Intégratives, CNRS (UPR 3212), Strasbourg, France; | |
| 关键词: Atypical hemolytic and uremic syndrome; Complement C3; Islets of Langerhans transplantation; Case report; | |
| DOI : 10.1186/s12882-020-02062-7 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundWe here report on the first observation of a C3 mutation that is related to atypical hemolytic and uremic syndrome (aHUS), which occurred in a pancreatic islet transplant patient. Immunosuppressive treatments, such as calcineurin inhibitors, have been linked to undesirable effects like nephrotoxicity.Case presentationA 40-year-old man with brittle diabetes, who was included in the TRIMECO trial, became insulin-independent 2 months after pancreatic islet transplantation. About 15 months after islet transplantation, the patient exhibited acute kidney injury due to aHUS. Despite plasma exchange and eculizumab treatment, the patient developed end-stage renal disease.A genetic workup identified a missense variant (p.R592Q) in the C3 gene. In vitro, this C3 variant had defective Factor I proteolytic activity with membrane proteins as cofactor proteins, which was thus classified as pathogenic. About 1 year after the aHUS episode, kidney transplantation was carried out under the protection of the specific anti-C5 monoclonal antibody eculizumab. The patient had normal kidney function, with preserved pancreatic islet function 4 years later.ConclusionsPancreatic islet transplantation could have triggered this aHUS episode, but this link needs to be clarified. Although prophylactic eculizumab maintains kidney allograft function, its efficacy still needs to be studied in larger populations.
【 授权许可】
CC BY
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202104243331858ZK.pdf | 620KB |
PDF